Search research articles
Contact Us
Filters
Showing results (71-80 of 86) with videos related to
Page
of 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 6, 2024
Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma
Georgina V Long, James Larkin, Dirk Schadendorf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 24, 2020
Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial
Suzanne L Topalian, Shailender Bhatia, Asim Amin, et al.
Neuro-Oncology
|
April 21, 2021
Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)
Hussein A Tawbi, Peter A Forsyth, F Stephen Hodi, et al.
The Lancet. Oncology
|
November 14, 2021
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study
Hussein A Tawbi, Peter A Forsyth, F Stephen Hodi, et al.
Cancer Cell
|
January 13, 2023
Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy
Gaopeng Li, Jae Eun Choi, Ilona Kryczek, et al.
Journal of Cancer Research and Clinical Oncology
|
December 7, 2016
Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma
Thomas M Atkinson, Jennifer L Hay, Alexander Shoushtari, et al.
The Lancet. Oncology
|
March 22, 2015
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S Weber, Sandra P D'Angelo, David Minor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 2021
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
Jedd D Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
JAMA
|
June 19, 2014
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial
Richard D Carvajal, Jeffrey A Sosman, Jorge Fernando Quevedo, et al.
Science Translational Medicine
|
December 3, 2011
Personalized oncology through integrative high-throughput sequencing: a pilot study
Sameek Roychowdhury, Matthew K Iyer, Dan R Robinson, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 86) with videos related to
Sort By:
Page
of 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 6, 2024
Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma
Georgina V Long, James Larkin, Dirk Schadendorf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 24, 2020
Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial
Suzanne L Topalian, Shailender Bhatia, Asim Amin, et al.
Neuro-Oncology
|
April 21, 2021
Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)
Hussein A Tawbi, Peter A Forsyth, F Stephen Hodi, et al.
The Lancet. Oncology
|
November 14, 2021
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study
Hussein A Tawbi, Peter A Forsyth, F Stephen Hodi, et al.
Cancer Cell
|
January 13, 2023
Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy
Gaopeng Li, Jae Eun Choi, Ilona Kryczek, et al.
Journal of Cancer Research and Clinical Oncology
|
December 7, 2016
Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma
Thomas M Atkinson, Jennifer L Hay, Alexander Shoushtari, et al.
The Lancet. Oncology
|
March 22, 2015
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S Weber, Sandra P D'Angelo, David Minor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 2021
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
Jedd D Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
JAMA
|
June 19, 2014
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial
Richard D Carvajal, Jeffrey A Sosman, Jorge Fernando Quevedo, et al.
Science Translational Medicine
|
December 3, 2011
Personalized oncology through integrative high-throughput sequencing: a pilot study
Sameek Roychowdhury, Matthew K Iyer, Dan R Robinson, et al.
Page
of 9